Compare CVS Health Corp (CVS) vs Zeta Global Holdings Corp (ZETA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Zeta Global Holdings Corp — how do they compare? CVS Health Corp trades at $95.09 (market cap $119.58B), while Zeta Global Holdings Corp trades at $28.58 (market cap $7.32B). The key difference: CVS Health Corp is far larger — about 16.3× Zeta Global Holdings Corp's market cap, and CVS Health Corp pays a 2.84% dividend while Zeta Global Holdings Corp pays none. Which is the better fit depends on your goals.
| CVS | ZETA | |
|---|---|---|
Market Cap | $119.58B | $7.32B |
Sector | Health | Technology |
52-Week High | $110.60 | $29.15 |
52-Week Low | $65.51 | $14.55 |
Enterprise Value | $181.93B | $7.20B |
Dividend Yield | 2.84% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $94.70, down 1.01% with strong technical support at $93-$91 levels. The company reported robust Q2 2026 earnings of $2.58 per share, beating estimates by 38%, while raising full-year guidance. Revenue growth accelerated to 7.3% year-over-year, driven by Aetna's recovery and retail strength. Analyst consensus remains overwhelmingly bullish with 84% buy ratings and a $115.90 price target representing 22% upside potential.
CVS presents compelling value with a 0.29 P/S ratio and positive earnings momentum, though net margins remain thin at 1.18%. Key risks include 2027 PBM pressure and healthcare regulatory changes. The stock's current technical weakness near support levels offers potential entry point for long-term investors seeking exposure to integrated healthcare services.
ZETA stock trades at $28.62, up 3.92% in the past 24 hours, with a bullish technical signal from moving averages and strong support at $28. The company reported its 20th consecutive beat-and-raise quarter in Q2 2026, with revenue up 44% year-over-year and achieving its first GAAP net income. Analyst consensus is strongly bullish with a $30.44 price target, and recent news highlights AI-driven growth and a partnership with Palantir.
The outlook for ZETA is positive due to robust revenue growth, expanding AI adoption, and improving profitability, but risks include a rich valuation with a P/S of 4.35 and EV/EBITDA of 95.89, execution challenges in integrating acquisitions, and competitive pressures in the marketing tech sector. The stock's proximity to its 52-week high suggests limited near-term upside without continued strong earnings performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Zeta Global Holdings Corp
Zeta Global is a leading data-driven marketing technology company that provides an omnichannel AI Marketing Cloud. By leveraging a proprietary data cloud of over 2.4 billion deterministic identities, it enables enterprise brands to acquire, grow, and retain customers through predictive intelligence and automated, agentic workflows.
Read more on ZETA →
